Sparsentan Decreased Proteinuria, but Failed to Slow eGFR Decline in FSGS: Data From the DUPLEX Trial – New Selection of Global Trials Out Now!
ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design and outcomes of the team's latest "Trial of the Month." Stay updated on the latest research and developments in kidney care: Access the new selection of global trials from the ISN-ACT initiative here. The "Trial of the Month" is available in several languages. Sparsentan Versus Irbesartan...